Core Framework & Diagram The Birth of ‘Immune Surveillance Theory’
July 24, 20261 Min Read The Origins of Cancer Immunology
July 24, 2026Your body hunts cancer cells every day
—— This idea was once ridiculed, then changed oncology.
I. Two people, same idea, two years apart
In 1957, Australian immunologist Frank Macfarlane Burnet, in his foundational Clonal Selection Theory, inserted what seemed an offhand corollary. The Clonal Selection Theory itself was already revolutionary enough — it explained how adaptive immunity generates precise responses to specific antigens through clonal expansion. But Burnet went further: since the immune system can distinguish 'self' from 'non-self,' shouldn't it also be able to identify cells within the body that have undergone genetic mutation? These mutated cells, at the genetic level, are no longer the original 'self' — they express abnormal proteins, appearing to the immune system as 'altered self,' and should theoretically be recognized and cleared. Burnet called this inference 'immunological surveillance.' In 1959, American internist and essayist Lewis Thomas, without citing Burnet, independently proposed almost the same idea, clearly describing it as a 'surveillance' function — the immune system is the body's patrol, continuously scanning, clearing cancerous cells when found. The ideas matched so precisely that scientific circles later attributed the theory's birth to both men, usually mentioning them together.
2. The first crisis: nude mice say 'no'
Immune surveillance theory faced a serious challenge in the 1970s from a special experimental animal: nude mice. Due to gene mutation (Foxn1 gene deletion), nude mice congenitally lack thymus and cannot produce mature T cells — meaning their adaptive immune systems are virtually blank. According to immune surveillance theory's logic, these mice without immune surveillance should have cancer incidence far higher than normal mice. But results were disappointing: nude mice's spontaneous tumor incidence wasn't significantly higher than normal mice. Many researchers interpreted this as a fatal blow to immune surveillance theory, and it was nearly abandoned by mainstream immunology in the 1970s to 1980s.
|
But later researchers found a critical omission in the nude mouse experiment: nude mice lack T cells but their innate immune system — including NK cells — is complete, even compensatorily enhanced due to absence of T cell regulation. Nude mice aren't 'without immune surveillance' but have 'a different form of immune surveillance.' True control experiments needed animals with both innate and adaptive immunity eliminated — impossible before gene knockout technology matured. |
3. Revival: gene knockout mice rewrite the answer
In the 1990s, gene knockout technology matured, and scientists could finally produce mice truly lacking specific immune components, precisely testing each component's contribution to tumor surveillance. Mice lacking IFN-γ or its receptor: spontaneous tumor incidence significantly elevated, and more sensitive to carcinogens (methylcholanthrene), with noticeably shorter tumor latency. This proved IFN-γ plays an irreplaceable role in immune surveillance — not only directly suppressing tumor cell proliferation but also coordinating immune cells' recognition and attack of tumors. Mice lacking perforin: spontaneous lymphoma incidence three to four times higher than normal mice, and chemically-induced tumors were larger and more invasive. This is direct genetic evidence that NK cells play an important role in tumor surveillance. Mice lacking RAG (genes essential for adaptive immunity): not only higher spontaneous tumor rates, but cells isolated from chemically-induced tumors had weaker growth capacity in immunologically normal mice — indicating these tumor cells had 'escaped' immune pressure in the RAG-deficient environment and therefore hadn't been 'trained' to develop stronger immune evasion capacity.
Schreiber's team's key 2001 paper in Nature systematically integrated this evidence, formally announcing immune surveillance theory's revival — but this time returning in a more precise, more complex form.
4. From 'immune surveillance' to 'cancer immunoediting' — the theory matures
In the early twenty-first century, Robert Schreiber and Lloyd Old proposed a more precise framework, upgrading immune surveillance to 'Cancer Immunoediting' theory, describing the complete process of the dynamic game between the immune system and tumors. Elimination: the stage originally described by Burnet and Thomas. The immune system, through coordination of innate immunity (NK cells, macrophages) and adaptive immunity (T cells, B cells), recognizes and destroys early cancerous cells. Most cancerous cells are cleared at this stage — we never know they existed. This process occurs every day. Equilibrium: some tumor cells survive under immune pressure but are suppressed by the immune system in a dynamic equilibrium state — tumors don't grow, but aren't completely eliminated. In this persistent 'arms race,' the immune system continuously kills tumor cells, while tumor cells through constant mutation select in each generation variants that better evade immune recognition. This stage can persist years to even decades. Escape: tumor cells complete immune evasion evolution — they may downregulate MHC-I (evading T cell recognition), upregulate PD-L1 (applying the T cell brake), recruit regulatory T cells (Treg) to establish immunosuppressive microenvironments, or suppress immune cell activity through secreting IL-10, TGF-β and other inhibitory cytokines.
5. Practical significance: understanding modern tumor treatment's logic
Understanding the three stages of cancer immunoediting is crucial for understanding modern tumor immunotherapy's logic — every immunotherapy approach can find its corresponding action node within this framework. PD-1/PD-L1 immune checkpoint inhibitors' essence is removing the immune brake established by tumors in the 'escape' stage, reactivating already-suppressed T cells and returning them to 'elimination' status. The premise is the presence in the body of T cells capable of recognizing the tumor, just suppressed by the brake — so for 'cold tumors' without sufficient tumor antigens, effects are often limited. Cancer early detection's immunological logic lies in intervening in the 'elimination' and 'equilibrium' stages rather than waiting until 'escape' to treat. In the equilibrium stage, tumor cells haven't yet completed full immune evasion evolution, and the immune system's ability to recognize them is still intact — intervention at this time is far more effective than in the escape stage. Understanding immunoediting also explains why some patients relapse after complete remission from immunotherapy: tumor cells weren't completely eliminated; a small number of immune-escape variants may have been preserved in the 'equilibrium' stage, re-entering 'escape' when immunotherapy pressure weakens.
Frequently Asked Questions